ella turner

ella turner

Followers 0
Following 0
From this data, digital biomarkers that offer insights into anatomical, physiological, and molecular events, and even behavior-related patterns in humans, have been acknowledged as viable inputs to understand, track, monitor and / or predict health-related outcomes.Over 85% of digital solutions for biomarkers are intended for patient monitoring purposesSuch solutions are currently available / being developed to monitor various digital biomarkers associated with neurological disorders (22%), respiratory disorders (17%), and infectious disorders (15%).In fact, over 15% of these solutions are being extensively used for monitoring patients with COVID-19.40 global events, focused on digital solutions for biomarkers, have been organized since 2016Around 40% of these were conferences, involving more than 25 unique organizers.Nearly USD 950 million invested by both private and public investors in this domain ~70% of the total capital raised by digital solutions for biomarkers developers was from venture capital funding, featuring the contributions of over 150 investors.In addition, over 65% was invested in companies focused on development of physiological / vocal digital biomarkers.
Advances in information technology and biomedical science have enabled the development of digital solutions for biomarkers, which, owing to the myriad of pertinent applications, are being increasingly adopted in modern healthcare practices Roots Analysis has announced the addition of “Digital Solutions for Biomarkers Market, 2021-2030” report to its list of offerings.The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these solutions over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.Amongst other elements, the report includes: A detailed assessment of the current market landscape of companies engaged in the development of digital solutions for biomarkers.An in depth analysis of the contemporary market trends, presented using five schematic representations.Elaborate profiles of key industry players that are developing / have developed digital solutions for biomarkers (shortlisted on the basis of the product portfolio).A detailed product competitiveness analysis of key industry players for the most popular type of biomarkers taking into consideration key product specific parameters.A detailed analysis of 40 recent global events (summits / forums / conferences / annual meetings) related to digital solutions for biomarkers, based on the several relevant parameters.An analysis of the investments made in the period between 2012 and Q3 2020 at various stages of development in companies that are engaged in this field.An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2014 and 2020.An analysis of various digital solutions for biomarkers focused initiatives carried out by big pharma players.A discussion on how the recent COVID-19 pandemic is likely to impact the overall digital solutions for biomarkers market, along with information on the key initiatives undertaken by big pharma players.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Content of SolutionSoftware Application + AI SupportSoftware Application + DeviceStandalone Software ApplicationOther Contents of Solutions Purpose of SolutionDiagnosisEarly ScreeningMonitoringPredictive Insights Type of BiomarkerCognitive BiomarkersIdiosyncratic BiomarkersPhysiological BiomarkersVocal BiomarkersOther Biomarkers Therapeutic AreasAutoimmune DisordersCardiovascular DisordersInfectious DisordersMental Health ProblemsNeurological DisordersRespiratory DisordersSubstance Use DisordersOthers Business ModelBusiness to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)Business to Consumer (Patients and Caregivers) Key Geographical Regions North AmericaEuropeAsia-PacificMiddle East and North Africa (MENA)Rest of the world  Transcripts of interviews held with the following senior level representatives of stakeholder companiesEdouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)Michael Seggev (Chief Commercial Officer, Vocalis Health) Key companies covered in the reportAkili InteractiveAiCureCogito CorpJanssen PharmaceuticalsHumaMindstrong HealthOuraPear TherapeuticsRocheSonde HealthVocalis HealthWinterlight Labs For more information, please click on the following link:https://www.rootsanalysis.com/reports/digital-biomarkers-market.html Other Recent OfferingsAI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030Connected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]                    
To order this 170+ page report, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Key Market Insights Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologiesIndustry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domainMajority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry playersStakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industryThe rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indicationsConsidering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savingsThe market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html                                                                                                               Table of Contents  PREFACE1.1.Chapter Outlines  EXECUTIVE SUMMARY  INTRODUCTION3.1.Fragment-based Drug Discovery (FBDD)Press Release: Variation 2 (Format 3) 3.5.1.Concluding Remarks  COMPANY COMPETITIVENESS ANALYSIS8.1.Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific  COST SAVING ANALYSIS9.1.Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-203010.4.3.
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade.It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed review of the overall landscape of fragment-based drug discovery library and service providers.Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).An analysis of the partnerships that have been established in the recent past.A detailed analysis on acquisition targets.An insightful competitiveness analysis of fragment-based drug discovery library and service providers.An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of TechniqueX-ray CrystallographyNuclear Magnetic ResonanceSurface Plasmon ResonanceOther Screening TechniquesType of ServiceLibrary ScreeningFragment ScreeningFragment OptimizationEnd UserIndustry PlayersNon-Industry PlayersKey Geographical Region North America (US and Canada)Europe (UK, France, Germany, Spain, Italy, and rest of Europe)Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) Key companies covered in the report:2bindCharles River LaboratoriesChemAxonComInnexCreative BiolabsCreative BiostructureCRELUXDomainexEvotecRed Glead DiscoveryPress Release: Variation 1 (Format 2) SARomics BiostructuresShanghai ChemPartnerSygnature DiscoveryVernalis Research For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Other recent offeringsDNA-Encoded Libraries: Platforms and Services MarketAntibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches) About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies.In addition to other elements, the study includes:A detailed review of the overall landscape of gene therapies and genome editing therapies.A discussion on the various types of viral and non-viral vectors.A world map representation, depicting the most active geographies, and a bull’s eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy.A discussion on the regulatory landscape related to gene therapies across various geographies.Detailed profiles of marketed and phase II/III and gene therapies.An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development.A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019.An analysis of the big biopharma players engaged in this domain.A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors.A discussion on the various operating models adopted by gene therapy developers for supply chain management.An analysis of the various factors that are likely to influence the pricing of gene-based therapies.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key therapeutic areasAutoimmune disordersCardiovascular diseasesGenetic disordersHematological disordersMetabolic disordersOphthalmic disordersOncological disordersOthersType of vectorAdeno associated virusAdenovirusHerpes simplex virus type 1LentivirusPlasmid DNARetrovirusVaccinia VirusType of therapyEx vivoIn vivoType of gene modificationGene augmentationImmunotherapyOncolytic therapyOthersRoute of administrationIntraarticularIntracerebellarIntramuscularIntradermalIntravenousIntravitrealIntravesicalSubretinalOthersKey geographical regionsNorth AmericaEuropeAsia-PacificTranscripts of interviews held with the following senior level representatives of stakeholder companiesAdam Rogers (CEO, Hemera Biosciences)Al Hawkins (CEO, Milo Biotechnology)Buel Dan Rodgers (Founder & CEO, AAVogen)Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)Jeffrey Hung (CCO, Vigene Biosciences)Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)Robert Jan Lamers (CEO, Arthrogen)Tom Wilton (Chief Business Officer, LogicBio Therapeutics) Key companies covered in the reportAdvantageneAdvaxisBioMarinbluebird bioFKD TherapiesFreeline TherapeuticsGenSight BiologicsGradalisInovio PharmaceuticalsMarsala BiotechOrchard TherapeuticsPfizerSarepta TherapeuticsSpark TherapeuticsTocagenTransgeneuniQure BiopharmaVBL TherapeuticsViroMed For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html Other Recent OfferingsViral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)CAR-T Therapies Market (2nd Edition), 2019-2030Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] 
 Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 670+ page report, which features 190+ figures and 340+ tables, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html Key Market Insights In the past four years, more than 31,000 patents related to gene therapies and gene editing have been filed / granted; this is indicative of the heightened pace of research in this domainPresently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indicationsMost of the therapeutic leads are in the early stages of clinical development; a variety of viral and non-viral vectors are being used to introduce different types of gene modifications in such therapiesAlthough start-ups and mid-sized companies are spearheading the innovation, several big biopharmaceutical companies are also actively engagedWith multiple approved products and several under development, price is one of the major concerns in this market; the future is likely to witness the establishment of more affordable pricing and reimbursement strategiesAs several candidates progress towards approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product’s launch cycleCMOs offering vector manufacturing services have become an integral part of the gene therapy supply chain, owing to their ability to overcome the various associated challengesSeveral investors, having realized the untapped opportunity within this emerging segment of genetic disorders, have invested over USD 16.5 billion across 280 instances, in the period between 2014 and 2019Overall, prevalent trends indicate that the market for gene therapies is poised to grow significantly as multiple late stage molecules get commercialized in the near future for the treatment of different therapeutic areasThe projected future opportunity is expected to be distributed across different types of gene modifications, therapy delivery routes and key geographical regions For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected] 
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions.Roots Analysis is pleased to announce the publication of its recent study titled, “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation”.The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these solutions over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.Amongst other elements, the report includes: A detailed assessment of the current market landscape of companies engaged in the development of digital therapeutic solutions.A detailed product competitiveness analysis of key industry players for the most popular therapeutic areas taking into consideration the strength of product portfolio and key product specific parameters.Elaborate profiles of key industry players that offer a several digital therapeutic solutions (shortlisted on the basis of the product portfolio).An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the several relevant parameters.An analysis of the investments made in the period between 2009 and 2020 at various stages of development in companies that are engaged in this field.An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020.A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space.A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and features of their products.An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Type of SolutionStandalone Software ApplicationSoftware Application + Device + Personal CoachSoftware Application + Device + AI SupportSoftware Application + DeviceSoftware Application + AI SupportSoftware Application + Personal CoachOther Types of Solutions Purpose of SolutionMedication ReplacementMedication Augmentation Type of TherapyCurativePreventive Business ModelBusiness to Consumer (Patients and Caregivers)Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies) Therapeutic AreasCardiovascular DisordersChronic PainMental Health ProblemsMetabolic DisordersNeurological DisordersRespiratory DisordersSleep DisordersSubstance Use DisordersOthers Key Geographical Regions North AmericaEuropeAsia-PacificRest of the world  Transcripts of interviews held with the following senior level representatives of stakeholder companiesEran Ofir (Co-Founder and Chief Executive Officer, Somatix)Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)Adam Kaufman (Chief Executive Officer, Canary Health)Vijay Ravindran (Chief Executive Officer, Floreo)Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)Amelie Janson (Communication Manager, Voluntis)Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company) Key companies covered in the reportAkili InteractiveBeats MedicalBig HealthBold HealthClick TherapeuticsCureAppdreemEhaveGingerHappify HealthinMotion VRKaia HealthLark HealthMahana TherapeuticsMindMazeNoomNOVOSIOmada HealthPalo Alto Health SciencesPear TherapeuticsVida HealthWelldocZOLL Medical For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html Other Recent OfferingsAR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030AI-Based Clinical Trial Solution Providers Market, 2020-2030Global Handheld Ultrasound Imaging Devices Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications.To order this 500+ page report, which features 160+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html Key Market Insights Nearly 230 digital therapeutic solutions are currently available / under developmentClose to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.Over 85% of digital therapeutic solutions are intended to replace medication Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%).Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019.
So far, more than 100 different types of cannabinoids have been identified and there is a growing body of evidence supporting the benefits of this class of compounds in offering symptomatic relief for a wide variety of chronic health conditions London Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.To order this 250+ page report, which features 140+ figures and 170+ tables, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html Key Market Insights  Over 175 drugs targeting the endocannabinoid system are currently under development Most cannabinoid-based drug candidates are being developed to target the CB1 and CB2 receptors.Nearly 45% of such drugs are presently being investigated in clinical trials, while 50% are in the preclinical / discovery phase.More than 60 companies claim to develop endocannabinoid system targeted therapeuticsPost 2010, there has been a significant rise in the number of companies working in this domain; such companies represent 63% of the total number of players.Further, grants (394) worth USD 147 million were awarded to research projects related to endocannabinoid system.
 Given the present scenario, many stakeholders are adopting such advanced marketing strategies to drive better consumer engagement through the use of immersive and interactive technologies  Roots Analysis has announced the addition of “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” report to its list of offerings.Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes.These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors.To order this 180+ page report, which features 45+ figures and 70+ tables, please visit https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html Key Market Insights More than 125 companies claim to offer different AR / VR based digital marketing services to the healthcare and pharma industry.The majority of players engaged in providing AR / VR based digital marketing services to the healthcare and pharmaceutical industry are small-sized companies (63%), followed by mid-sized (32%) and large players (5%).Majority (18%) of the instances were recorded in the year 2018.
To order this 200+ page report, which features 85+ figures and 100+ tables, please visit  China Pharmaceutical Contract Manufacturing Services Market, 2020-2030 Key Market Insights Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturingCMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providersThe current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few yearsBig pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R centers and manufacturing facilities focused on pharmaceutical productsInnovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html Table of Contents  PREFACE 1.1.Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies5.2.1.Analysis by Manufacturing Facilities 5.3.Big Pharma Players: List of Initiatives9.2.1.CMOs with Manufacturing Facilities in China: Installed Capacity11.3.1.Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies13.7.3.
Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region.Amongst other elements, the report features:A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Geographical RegionsEastern ChinaSouthern ChinaNorthern China  Type of ProductActive Pharmaceutical Ingredients (APIs)Drug Products Type of Drug ProductSolidLiquid / Semi-SolidInjectableOthers Scale of OperationClinicalCommercial Company SizeSmallMid-SizedLarge / Very Large  Key players covered in the report2Y-ChemAurisco PharmaceuticalChemPartnerDorrapharmaHubei Biocause PharmaceuticalInfoarkNingbo Menovo PharmaceuticalShandong Xinhua PharmaceuticalShanghai Acebright PharmaceuticalsSTA PharmaceuticalZhejiang Huahai Pharmaceutical For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020 – 2030HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] 
Roots Analysis has done a detailed study on Prefilled Syringes, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 800+ page report, which features 800+ figures and 150+ tables, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html Key Market Insights Presently, around 80 types of prefilled syringes are available in the market, and several companies claim to be engaged in the manufacturing of both glass and plastic variants of such versatile drug delivery solutionsOver 140 drugs and vaccines have either been marketed or have undergone clinical investigation (since 2013) for delivery via prefilled syringes for the treatment of a variety of disease indicationsIn order to gain a competitive edge in the market, prefilled syringe manufacturers are actively engaged in developing patient friendly products, with improved safety features and solutionsThe market is also characterized by the presence of many contract service providers, spread across the world, offering fill / finish services in prefilled syringesSeveral big pharma companies are actively engaged in strengthening their pipeline of injectable drugs across various therapeutic areasAn evaluation of 280+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via prefilled syringes in the near future, paving way for new partnershipsThe current market opportunity is well distributed across different therapeutic areas, molecule types and geographical regions; the market is likely to grow at a steady pace over the coming yearsGlass, single chamber prefilled syringes dominate the current market; however, the demand for plastic devices is anticipated to witness a relatively higher growth in the foreseen future For more information, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html  Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]
Prefilled syringes present an attractive packaging option that doubles as an easy-to-use drug delivery device, and a product life cycle management tool.Consequently, they have become indispensable within the modern healthcare industry.To order this 800+ page report, which features 800+ figures and 150+ tables, please visit  https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html   The financial opportunity within the prefilled syringes market has been analyzed across the following segments:Target therapeutic areaAutoimmune disordersInfectious diseasesNeurological disordersBlood disordersOncological disordersPsychiatric disordersRespiratory disordersCardiovascular disordersMetabolic disordersOphthalmic diseasesOrthopedic disordersOthers Type of syringeSpecialty syringes Type of syringe barrel materialGlassPlastic Number of barrel chambersSingle chamberDual chamber Key geographical regionsNorth AmericaEuropeLatin AmericaAsia PacificMiddle East and Africa The Prefilled Syringes Market (5th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: Becton DickinsonWest PharmaceuticalGerresheimerOmpiSchottNiproWEGO Prefills Pharmaceutical PackagingTaisei KakoTerumoAguettantArteJO PharmaPfizer InjectablesShandong Pharmaceutical GlassShandong Zibo Minkang Pharmaceutical PackingVetter Pharma Table of Contents  PREFACE  EXECUTIVE SUMMARY  INTRODUCTION TO PREFILLED SYRINGES 4 PREFILLED SYRINGES: MARKET OVERVIEW 5 PRODUCT COMPETITIVENESS ANALYSIS 6 MANUFACTURERS OF PREFILLED SYRINGES 7 NEEDLESTICK INJURIES 8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES 9 PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW  10 KEY THERAPEUTIC AREAS 11 PREFILLED SYRINGES: LIKELY DRUG CANDIDATES AND PARTNER  ANALYSIS 12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES  13 SPECIALTY PREFILLED SYRINGES 14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES 15 MARKET SIZING AND OPPORTUNITY ANALYSIS 16 GROWTH DRIVERS 17 SWOT ANALYSIS 18 PREFILLED SYRINGE COMPONENT MANUFACTURERS 19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES 20 CASE STUDY: AUTOINJECTORS 21 CONCLUDING REMARKS 22 INTERVIEW TRANSCRIPTS 23 APPENDIX 1: TABULATED DATA 24 APPENDIX 2: LIST OF COMPANIES To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]   
To order this 170+ page report, which features 55+ figures and 80+ tables, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Key Market Insights Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologiesIndustry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domainMajority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry playersStakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industryThe rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indicationsConsidering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savingsThe market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html                                                                                                               Table of Contents  PREFACE1.1.Chapter Outlines  EXECUTIVE SUMMARY  INTRODUCTION3.1.Fragment-based Drug Discovery (FBDD)Press Release: Variation 2 (Format 3) 3.5.1.Concluding Remarks  COMPANY COMPETITIVENESS ANALYSIS8.1.Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific  COST SAVING ANALYSIS9.1.Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-203010.4.3.
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade.It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed review of the overall landscape of fragment-based drug discovery library and service providers.Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).An analysis of the partnerships that have been established in the recent past.A detailed analysis on acquisition targets.An insightful competitiveness analysis of fragment-based drug discovery library and service providers.An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of TechniqueX-ray CrystallographyNuclear Magnetic ResonanceSurface Plasmon ResonanceOther Screening TechniquesType of ServiceLibrary ScreeningFragment ScreeningFragment OptimizationEnd UserIndustry PlayersNon-Industry PlayersKey Geographical Region North America (US and Canada)Europe (UK, France, Germany, Spain, Italy, and rest of Europe)Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) Key companies covered in the report:2bindCharles River LaboratoriesChemAxonComInnexCreative BiolabsCreative BiostructureCRELUXDomainexEvotecRed Glead DiscoveryPress Release: Variation 1 (Format 2) SARomics BiostructuresShanghai ChemPartnerSygnature DiscoveryVernalis Research For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html Other recent offeringsDNA-Encoded Libraries: Platforms and Services MarketAntibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches) About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
Advances in information technology and biomedical science have enabled the development of digital solutions for biomarkers, which, owing to the myriad of pertinent applications, are being increasingly adopted in modern healthcare practices Roots Analysis has announced the addition of “Digital Solutions for Biomarkers Market, 2021-2030” report to its list of offerings.The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these solutions over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.Amongst other elements, the report includes: A detailed assessment of the current market landscape of companies engaged in the development of digital solutions for biomarkers.An in depth analysis of the contemporary market trends, presented using five schematic representations.Elaborate profiles of key industry players that are developing / have developed digital solutions for biomarkers (shortlisted on the basis of the product portfolio).A detailed product competitiveness analysis of key industry players for the most popular type of biomarkers taking into consideration key product specific parameters.A detailed analysis of 40 recent global events (summits / forums / conferences / annual meetings) related to digital solutions for biomarkers, based on the several relevant parameters.An analysis of the investments made in the period between 2012 and Q3 2020 at various stages of development in companies that are engaged in this field.An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2014 and 2020.An analysis of various digital solutions for biomarkers focused initiatives carried out by big pharma players.A discussion on how the recent COVID-19 pandemic is likely to impact the overall digital solutions for biomarkers market, along with information on the key initiatives undertaken by big pharma players.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Content of SolutionSoftware Application + AI SupportSoftware Application + DeviceStandalone Software ApplicationOther Contents of Solutions Purpose of SolutionDiagnosisEarly ScreeningMonitoringPredictive Insights Type of BiomarkerCognitive BiomarkersIdiosyncratic BiomarkersPhysiological BiomarkersVocal BiomarkersOther Biomarkers Therapeutic AreasAutoimmune DisordersCardiovascular DisordersInfectious DisordersMental Health ProblemsNeurological DisordersRespiratory DisordersSubstance Use DisordersOthers Business ModelBusiness to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)Business to Consumer (Patients and Caregivers) Key Geographical Regions North AmericaEuropeAsia-PacificMiddle East and North Africa (MENA)Rest of the world  Transcripts of interviews held with the following senior level representatives of stakeholder companiesEdouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)Michael Seggev (Chief Commercial Officer, Vocalis Health) Key companies covered in the reportAkili InteractiveAiCureCogito CorpJanssen PharmaceuticalsHumaMindstrong HealthOuraPear TherapeuticsRocheSonde HealthVocalis HealthWinterlight Labs For more information, please click on the following link:https://www.rootsanalysis.com/reports/digital-biomarkers-market.html Other Recent OfferingsAI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030Connected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]                    
From this data, digital biomarkers that offer insights into anatomical, physiological, and molecular events, and even behavior-related patterns in humans, have been acknowledged as viable inputs to understand, track, monitor and / or predict health-related outcomes.Over 85% of digital solutions for biomarkers are intended for patient monitoring purposesSuch solutions are currently available / being developed to monitor various digital biomarkers associated with neurological disorders (22%), respiratory disorders (17%), and infectious disorders (15%).In fact, over 15% of these solutions are being extensively used for monitoring patients with COVID-19.40 global events, focused on digital solutions for biomarkers, have been organized since 2016Around 40% of these were conferences, involving more than 25 unique organizers.Nearly USD 950 million invested by both private and public investors in this domain ~70% of the total capital raised by digital solutions for biomarkers developers was from venture capital funding, featuring the contributions of over 150 investors.In addition, over 65% was invested in companies focused on development of physiological / vocal digital biomarkers.
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare.The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.Presently, a variety of other such chemical entities and molecular glues are under investigation.In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:ArvinasCaptor TherapeuticsCelgeneGenetechKymera TherapeuticsMission TherapeuticsProgenraRadius HealthSanofi GenzymeZenopharm Table of Contents  Preface Executive Summary Introduction Current Market Landscape Company Profiles Clinical Trial Analysis KOL Analysis Publication Analysis Funding and Investment Analysis Partnerships and Collaborations Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]
1
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html  Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
More

Top